We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) is set to report fourth-quarter fiscal 2016 earnings results on Nov 3. Last quarter, the company reported earnings of $2.35 per share, which beat the Zacks Consensus Estimate of $2.19.
Notably, Becton, Dickinson’s results compared favorably with the Zacks Consensus Estimate in the last four quarters, resulting in an average beat of 6.25%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Becton, Dickinson's innovative product pipeline is a key catalyst in our view. A plethora of regulatory approvals both in the U.S. and International markets are helping the company to rapidly expand its product portfolio.
Management at Becton, Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the fiscal fourth quarter.
Additionally, partnerships and collaborations are also providing the company a competitive edge. Moreover, the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton, Dickinson.
However, an unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year. Tough year-over-year comparisons in the fiscal fourth quarter also pose as concerns.
Our proven model does not conclusively show that Becton, Dickinson is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Becton, Dickinson currently has an Earnings ESP of -1.44%. This is because the Most Accurate estimate stands at $2.06 and the Zacks Consensus Estimate is pegged at $2.09. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: Becton, Dickinson has a Zacks Rank #3 which increases the predictive power of ESP. However, a negative ESP makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Penumbra, Inc. (PEN - Free Report) has an Earnings ESP of +45.46% and a Zacks Rank #3.
Invuity, Inc. has an Earnings ESP of +1.61% and a Zacks Rank #2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton, Dickinson (BDX) Q4 Earnings: What's in the Cards?
Becton, Dickinson and Company (BDX - Free Report) is set to report fourth-quarter fiscal 2016 earnings results on Nov 3. Last quarter, the company reported earnings of $2.35 per share, which beat the Zacks Consensus Estimate of $2.19.
Notably, Becton, Dickinson’s results compared favorably with the Zacks Consensus Estimate in the last four quarters, resulting in an average beat of 6.25%.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Becton, Dickinson's innovative product pipeline is a key catalyst in our view. A plethora of regulatory approvals both in the U.S. and International markets are helping the company to rapidly expand its product portfolio.
Management at Becton, Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the fiscal fourth quarter.
Additionally, partnerships and collaborations are also providing the company a competitive edge. Moreover, the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton, Dickinson.
However, an unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year. Tough year-over-year comparisons in the fiscal fourth quarter also pose as concerns.
BECTON DICKINSO Price and EPS Surprise
BECTON DICKINSO Price and EPS Surprise | BECTON DICKINSO Quote
Earnings Whispers
Our proven model does not conclusively show that Becton, Dickinson is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.
Zacks ESP: Becton, Dickinson currently has an Earnings ESP of -1.44%. This is because the Most Accurate estimate stands at $2.06 and the Zacks Consensus Estimate is pegged at $2.09. Please check our Earnings ESP Filter that enables you find stocks that are expected to come out with earnings surprises.
Zacks Rank: Becton, Dickinson has a Zacks Rank #3 which increases the predictive power of ESP. However, a negative ESP makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Glaukos Corporation (GKOS - Free Report) has an Earnings ESP of +100% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra, Inc. (PEN - Free Report) has an Earnings ESP of +45.46% and a Zacks Rank #3.
Invuity, Inc. has an Earnings ESP of +1.61% and a Zacks Rank #2.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>